These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 34052813)

  • 1. Hypocretin/Orexin Receptor Pharmacology and Sleep Phases.
    Sun Y; Tisdale RK; Kilduff TS
    Front Neurol Neurosci; 2021; 45():22-37. PubMed ID: 34052813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
    Hoyer D; Jacobson LH
    Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of hypocretin receptor-2 signaling in dopaminergic neurons induces hyperarousal and enhanced cognition but impaired inhibitory control.
    Bandarabadi M; Li S; Aeschlimann L; Colombo G; Tzanoulinou S; Tafti M; Becchetti A; Boutrel B; Vassalli A
    Mol Psychiatry; 2024 Feb; 29(2):327-341. PubMed ID: 38123729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status.
    Mieda M; Sakurai T
    CNS Drugs; 2013 Feb; 27(2):83-90. PubMed ID: 23359095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice.
    Yukitake H; Fujimoto T; Ishikawa T; Suzuki A; Shimizu Y; Rikimaru K; Ito M; Suzuki M; Kimura H
    Pharmacol Biochem Behav; 2019 Dec; 187():172794. PubMed ID: 31654653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OX2R-selective orexin agonism is sufficient to ameliorate cataplexy and sleep/wake fragmentation without inducing drug-seeking behavior in mouse model of narcolepsy.
    Yamamoto H; Nagumo Y; Ishikawa Y; Irukayama-Tomobe Y; Namekawa Y; Nemoto T; Tanaka H; Takahashi G; Tokuda A; Saitoh T; Nagase H; Funato H; Yanagisawa M
    PLoS One; 2022; 17(7):e0271901. PubMed ID: 35867683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The present and future of synthetic orexin receptor agonists.
    Saitoh T; Sakurai T
    Peptides; 2023 Sep; 167():171051. PubMed ID: 37422012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promotion of Wakefulness and Energy Expenditure by Orexin-A in the Ventrolateral Preoptic Area.
    Mavanji V; Perez-Leighton CE; Kotz CM; Billington CJ; Parthasarathy S; Sinton CM; Teske JA
    Sleep; 2015 Sep; 38(9):1361-70. PubMed ID: 25845696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of action of suvorexant.
    Stahl SM
    CNS Spectr; 2016 Jun; 21(3):215-8. PubMed ID: 27322687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excitation of Cortical nNOS/NK1R Neurons by Hypocretin 1 is Independent of Sleep Homeostasis.
    Williams RH; Black SW; Thomas AM; Piquet J; Cauli B; Kilduff TS
    Cereb Cortex; 2019 Mar; 29(3):1090-1108. PubMed ID: 29462275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The orexin story, sleep and sleep disturbances.
    Pizza F; Barateau L; Dauvilliers Y; Plazzi G
    J Sleep Res; 2022 Aug; 31(4):e13665. PubMed ID: 35698789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The roles of orexins in sleep/wake regulation.
    Mieda M
    Neurosci Res; 2017 May; 118():56-65. PubMed ID: 28526554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypocretin and its emerging role as a target for treatment of sleep disorders.
    Cao M; Guilleminault C
    Curr Neurol Neurosci Rep; 2011 Apr; 11(2):227-34. PubMed ID: 21170610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypocretin antagonists in insomnia treatment and beyond.
    Ruoff C; Cao M; Guilleminault C
    Curr Pharm Des; 2011; 17(15):1476-82. PubMed ID: 21476951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the hypocretinergic system in the integration of networks that dictate the states of arousal.
    Winsky-Sommerer R; Boutrel B; De Lecea L
    Drug News Perspect; 2003 Oct; 16(8):504-12. PubMed ID: 14668948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
    Roecker AJ; Cox CD; Coleman PJ
    J Med Chem; 2016 Jan; 59(2):504-30. PubMed ID: 26317591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
    Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the orexin system in stress response.
    Sargin D
    Neuropharmacology; 2019 Aug; 154():68-78. PubMed ID: 30266600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toward the Mysteries of Sleep.
    Yanagisawa M
    Keio J Med; 2019; 68(1):27. PubMed ID: 30905886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypocretin-2-saporin lesions of the lateral hypothalamus produce narcoleptic-like sleep behavior in the rat.
    Gerashchenko D; Kohls MD; Greco M; Waleh NS; Salin-Pascual R; Kilduff TS; Lappi DA; Shiromani PJ
    J Neurosci; 2001 Sep; 21(18):7273-83. PubMed ID: 11549737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.